glp 1 agonists for alcohol use disorder GLP-1 medications get at the heart of addiction: study – WashU Medicine GLP-1 Anti-Obesity Rx and Alcohol

We see Novo Nordisk and Eli Lilly as overvalued despite assuming that a quarter of US adults with obesity will be on GLP-1 therapies by 2031, leading to a GLP-1 market north of $200 billion in 2031, before generic semaglutide (Wegovy/Ozempic/Rybelsus) launches. Competition rises

Clinical evidences have demonstrated that glibenclamide, a prototypical sulfonylurea, is associated with a significantly increased cancer risk occurrence [107]

The most common side effects of dulaglutide are nausea, vomiting, and diarrhea

Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events

This review also proposed new strategies for the design of future clinical trials on GLP-1 RAs for both AD and PD

Novo Nordisk A/S, now Europes most valuable company with a market capitalization of roughly $454.5 billion as of Oct